Allakos Inc. (ALLK)
NASDAQ: ALLK · IEX Real-Time Price · USD
1.050
-0.010 (-0.94%)
At close: Apr 23, 2024, 4:00 PM
1.090
+0.040 (3.81%)
After-hours: Apr 23, 2024, 6:48 PM EDT
Company Description
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
The company was incorporated in 2012 and is headquartered in San Carlos, California.
Allakos Inc.
Country | United States |
Founded | 2012 |
IPO Date | Jul 19, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 131 |
CEO | Dr. Robert Alexander Ph.D. |
Contact Details
Address: 825 Industrial Road, Suite 500 San Carlos, California 94070 United States | |
Phone | 650-597-5002 |
Website | allakos.com |
Stock Details
Ticker Symbol | ALLK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001564824 |
CUSIP Number | 01671P100 |
ISIN Number | US01671P1003 |
Employer ID | 45-4798831 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Robert Alexander Ph.D. | Chief Executive Officer and Director |
Dr. Adam L. Tomasi Ph.D. | President |
Baird Radford III | Chief Financial Officer |
Mary Cromwell Ph.D. | Chief Technical Officer |
Dr. Chin Lee M.D., M.P.H. | Chief Medical Officer |
Alan Chang | Director of Medical Affairs and Data Analytics |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 23, 2024 | ARS | Filing |
Apr 23, 2024 | 8-K | Current Report |
Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
Mar 19, 2024 | 144 | Filing |
Mar 14, 2024 | 10-K | Annual Report |
Mar 14, 2024 | 8-K | Current Report |
Mar 6, 2024 | 144 | Filing |
Mar 5, 2024 | 144 | Filing |
Mar 4, 2024 | 144 | Filing |
Feb 26, 2024 | 8-K | Current Report |